ORION CORPORATION
- Country
- 🇫🇮Finland
- Ownership
- -
- Established
- 1917-01-01
- Employees
- -
- Market Cap
- $7.3B
- Website
- https://www.orion.fi/
Clinical Trials
46
Trial Phases
3 Phases
Drug Approvals
28
Drug Approvals
Budesonide Inhalation Powder
- Product Name
- 布地奈德吸入粉雾剂
- Approval Number
- 国药准字HJ20140422
- Approval Date
- Jul 23, 2024
Budesonide Inhalation Powder
- Product Name
- 布地奈德吸入粉雾剂
- Approval Number
- 国药准字HJ20140421
- Approval Date
- Jul 23, 2024
Salbutamol Sulfate Inhalation Powder
- Product Name
- 硫酸沙丁胺醇吸入粉雾剂
- Approval Number
- 国药准字HJ20130596
- Approval Date
- Dec 11, 2023
Warfarin Sodium Tablets
- Product Name
- Marevan
- Approval Number
- 国药准字HJ20171095
- Approval Date
- Oct 25, 2022
Entacapone,Levodopa and Carbidopa Tablets（Ⅲ）
- Product Name
- 达灵复
- Approval Number
- 国药准字HJ20181002
- Approval Date
- Jun 13, 2022
Entacapone,Levodopa and Carbidopa Tablets（Ⅱ）
- Product Name
- 达灵复
- Approval Number
- 国药准字HJ20171148
- Approval Date
- Jun 13, 2022
Entacapone,Levodopa and Carbidopa Tablets（Ⅳ）
- Product Name
- 达灵复
- Approval Number
- 国药准字HJ20181219
- Approval Date
- Jun 13, 2022
Entacapone,Levodopa and Carbidopa Tablets
- Product Name
- 达灵复
- Approval Number
- 国药准字HJ20181001
- Approval Date
- Jun 13, 2022
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
News
Orion and Glykos Extend ADC Partnership to Develop Six Next-Generation Cancer Therapies
Orion Corporation and Glykos Finland have extended their research collaboration to develop up to six next-generation antibody-drug conjugates (ADCs) targeting solid tumors.
Orion and Shilpa Medicare Partner to Bring Recombinant Human Albumin to European Market
Orion Corporation has secured exclusive rights to distribute, market, and sell Shilpa Medicare's Recombinant Human Albumin across Europe, strengthening their position in value-add hospital generics.
MSD Expands Opevesostat Clinical Program to Include Breast, Endometrial, and Ovarian Cancers
MSD has initiated a new Phase 2 clinical trial to evaluate opevesostat (MK-5684) in women's cancers, expanding beyond its current prostate cancer program.
Bayer Seeks FDA Approval to Expand Nubeqa's Indication for Metastatic Hormone-Sensitive Prostate Cancer
Bayer has submitted a supplemental New Drug Application (sNDA) to the FDA for Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT).
ARANOTE Trial: Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
The ARANOTE trial demonstrated that darolutamide plus androgen deprivation therapy (ADT) significantly improves radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Darolutamide Plus ADT Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
Darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
NUBEQA® (darolutamide) Plus ADT Significantly Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
The Phase III ARANOTE trial demonstrated that NUBEQA plus androgen deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) in mHSPC patients.
Darolutamide Approved in China for Metastatic Hormone-Sensitive Prostate Cancer
The Chinese NMPA has approved darolutamide (Nubeqa) plus docetaxel for metastatic hormone-sensitive prostate cancer (mHSPC).
MHRA and NHS England Fast-Track Novel Prostate Cancer Treatment Darolutamide Combination Therapy
A groundbreaking combination therapy of NUBEQA (Darolutamide) with ADT and docetaxel receives accelerated approval from MHRA through Project Orbis for metastatic hormone-sensitive prostate cancer treatment.